Platelet transfusion for patients with cancer.

BACKGROUND Platelet transfusion is a critical and often necessary aspect of managing cancer. Low platelet counts frequently lead to bleeding complications; however, the drugs used to combat malignancy commonly lead to decreased production and destruction of the very cell whose function is essential to stop bleeding. The transfusion of allogeneic platelet products helps to promote hemostasis, but alloimmunization may make it difficult to manage other complications associated with cancer. METHODS The literature relating to platelet transfusion in patients with cancer was reviewed. RESULTS Platelet storage, dosing, transfusion indications, and transfusion response are essential topics for health care professionals to understand because many patients with cancer will require platelet transfusions during the course of treatment. The workup and differentiation of non-immune-mediated compared with immune-mediated platelet refractoriness are vital because platelet management is different between types of refractoriness. CONCLUSIONS A combination of appropriate utilization of platelet inventory and laboratory testing coupled with communication between those caring for patients with cancer and those providing blood products is essential for effective patient care.

[1]  Y. Chuai,et al.  Thrombopoietin receptor agonists for prevention and treatment of chemotherapy-induced thrombocytopenia in patients with solid tumours. , 2017, The Cochrane database of systematic reviews.

[2]  Benjamin Djulbegovic,et al.  Platelet Transfusion: A Clinical Practice Guideline From the AABB , 2015, Annals of Internal Medicine.

[3]  C. Schiffer.  They took a mulligan and mostly got it right … the issue of prophylactic platelet transfusion for patients receiving autologous stem cell transplantation , 2014, Transfusion.

[4]  H. Liebman.  Thrombocytopenia in cancer patients. , 2014, Thrombosis research.

[5]  Salamatina Os,et al.  Evaluation of platelet cross-matching in the management of patients refractory to platelet transfusions. , 2014 .

[6]  P. Rebulla,et al.  Utility of cross‐matched platelet transfusions in patients with hypoproliferative thrombocytopenia: a systematic review , 2014, Transfusion.

[7]  B. Dumitriu,et al.  Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. , 2014, Blood.

[8]  S. Assmann,et al.  The impact of platelet transfusion characteristics on posttransfusion platelet increments and clinical bleeding in patients with hypoproliferative thrombocytopenia. , 2012, Blood.

[9]  B. Konkle.  Acquired disorders of platelet function. , 2011, Hematology. American Society of Hematology. Education Program.

[10]  L. Corash.  Bacterial contamination of platelet components: potential solutions to prevent transfusion-related sepsis , 2011, Expert review of hematology.

[11]  J. McCullough.  Overview of platelet transfusion. , 2010, Seminars in hematology.

[12]  G. Stack,et al.  Drug-induced thrombocytopenia. , 2009, Archives of pathology & laboratory medicine.

[13]  E. Hod,et al.  Platelet transfusion refractoriness , 2008, British journal of haematology.

[14]  S. Wendel,et al.  Incidence of transfusion‐induced platelet‐reactive antibodies evaluated by specific assays for the detection of human leucocyte antigen and human platelet antigen antibodies , 2007, Vox sanguinis.

[15]  Edward J. Lee,et al.  Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. , 2005, Blood.

[16]  J. Gornbein,et al.  Selecting donors of platelets for refractory patientson the basis of HLA antibody specificity , 2000, Transfusion.

[17]  B. Balint,et al.  [Therapeutic use of blood products and their recombinant analogs in patients with disorders of hemostasis]. , 2000, Vojnosanitetski pregled.

[18]  P. Mintz,et al.  The evaluation and management of platelet refractoriness and alloimmunization. , 2000, Transfusion medicine reviews.

[19]  L. Corash,et al.  Corrected count increment and percent platelet recovery as measures of posttransfusion platelet response: problems and a solution , 1999, Transfusion.

[20]  C. Schiffer.  Prophylactic platelet transfusion , 1992, Transfusion.

[21]  S. Slichter,et al.  A model to determine required pool size for HLA‐typed community donor apheresis programs , 1989, Transfusion.

[22]  F. Grumet,et al.  Platelet transfusion therapy; the selection of compatible platelet donors for refractory patients by lymphocyte HL-A typing. , 1969, The New England journal of medicine.

[23]  R. Aster.  Pooling of platelets in the spleen: role in the pathogenesis of "hypersplenic" thrombocytopenia. , 1966, The Journal of clinical investigation.

[24]  L. Kux.  OF HEALTH AND HUMAN SERVICES Food and Drug Administration , 2014 .

[25]  S. Slichter.  Evidence-based platelet transfusion guidelines. , 2007, Hematology. American Society of Hematology. Education Program.

[26]  Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. , 1997, The New England journal of medicine.

[27]  S. Slichter.  Platelet crossmatch testing for donor selection. , 1982, Progress in clinical and biological research.

[28]  Slichter Sj.  Platelet crossmatch testing for donor selection. , 1982 .

[29]  T. Greenwalt,et al.  American Association of Blood Banks , 1959 .